Arbutus Biopharma's total assets for Q3 2024 were $140.44M, a decrease of -12.25% from the previous quarter. ABUS total liabilities were $33.55M for the fiscal quarter, a -10.74% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.